After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

The brain-computer interface technology personalizes therapy based on an individual’s brain activity.

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...